Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900275 · ClinicalTrials.gov registry record
Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults
A clinical trial, sponsored by Denver Health and Hospital Authority.
- Completed
- Registry status
- 57
- Enrollment target
NCT01900275 is a clinical trial that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 57 participants.
The verdict
NCT01900275 has completed, sponsored by Denver Health and Hospital Authority.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
Study Summary
Across the world, the most common cause of dying in the ICU is a disease called "sepsis". Sepsis is a disease in which the body's protective response to infection becomes too intense, unnecessarily damaging important organs in the body. Kidney damage during sepsis is particularly bad, as a person's chance of survival drops significantly when he or she develops kidney failure. This study plans to learn more about how to detect (and thus prevent) kidney failure early in sepsis. The current tests doctors use only detect kidney failure once it's already happened. We must therefore find better ways of detecting kidney failure earlier, when there is still a chance to protect the kidneys. In this study, patients will provide a one-time sample of urine. We will check this urine for signs of a protein called "heparanase", which we believe is important in early kidney failure. We will then see if high heparanase activity in urine predicts the risk of developing kidney failure. We will compare results from patients with sepsis with results from patients with trauma, allowing us to determine if heparanase is only important in sepsis kidney failure.
Interventions
- OTHER Urine collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01900275
The ClinicalTrials.gov registry entry for NCT01900275 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Urine collection is the first listed.
NCT01900275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01900275 about?
NCT01900275 is a clinical study titled "Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults". Across the world, the most common cause of dying in the ICU is a disease called "sepsis". Sepsis is a disease in which the body's protective response to infection becomes too intense, unnecessarily damaging important organs in the body. Kidney damage during sepsis is particularly bad, as a person's ...
What is the current status of trial NCT01900275?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2013-07.
What interventions are being tested in trial NCT01900275?
The interventions under investigation include: Urine collection (OTHER).
Who is sponsoring clinical trial NCT01900275?
This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.